4CLL1 Antibody

Antibody Nomenclature and Validation

Antibody names typically reflect their target antigen or clinical purpose (e.g., anti-CD38 for daratumumab) . The designation "4CLL1" does not correspond to:

• Known CLL-associated antigens: CD19, CD20, CD38, or BCMA .

• Structural classifications: IgG subtypes (e.g., IgG1, IgG4) or bispecific formats (e.g., DuoBody-PD-L1×4-1BB) .

• Clinical-stage compounds: Approved or experimental therapies for CLL (e.g., ibrutinib, venetoclax) .

Potential Sources of Confusion

The term "4CLL1" may arise from:

• Typographical errors: Misrendering of "CLL1" (a hypothetical antigen) or "4-1BB" (a co-stimulatory receptor targeted in bispecific antibodies like GEN1046) .

• Internal project codes: Proprietary identifiers from undisclosed preclinical research.

• Misinterpretation of data: Incorrect association with studies on APRIL antagonistic antibodies (e.g., hAPRIL.01A) or anti-PD-1 Fc variants .

Relevant Antibody Classes in CLL Research

While "4CLL1" remains unverified, below are validated antibody targets in CLL therapy:

Scientific and Clinical Implications

• Antibody validation: Commercial antibodies require rigorous specificity testing to avoid batch-to-batch variability . No such data exists for "4CLL1."

• Fc engineering: Fc-null or modified antibodies (e.g., anti-PD-1 mIgG1-N297A) show enhanced efficacy in CLL models by avoiding FcγR-mediated T-cell depletion .

• Bispecific platforms: Antibodies like DuoBody-PD-L1×4-1BB (GEN1046) demonstrate synergy between PD-L1 blockade and 4-1BB agonism in preclinical studies .

Recommendations for Further Inquiry

1. Verify nomenclature: Cross-reference "4CLL1" with institutional databases or proprietary pipelines.

2. Explore analogous targets: Investigate APRIL/BAFF inhibitors (e.g., hAPRIL.01A) or Fc-optimized anti-CD20 antibodies .

3. Consult regulatory filings: Search clinicaltrials.gov or EMA/FDA databases for unpublished codes.